Log in to save to my catalogue

Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) ad...

Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) ad...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_2688057447

Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) administered via nebulizer

About this item

Full title

Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) administered via nebulizer

Publisher

United States: Public Library of Science

Journal title

PloS one, 2022-07, Vol.17 (7), p.e0271066

Language

English

Formats

Publication information

Publisher

United States: Public Library of Science

More information

Scope and Contents

Contents

As ACE2 is the critical SARS-CoV-2 receptor, we hypothesized that aerosol administration of clinical grade soluble human recombinant ACE2 (APN01) will neutralize SARS-CoV-2 in the airways, limit spread of infection in the lung, and mitigate lung damage caused by deregulated signaling in the renin-angiotensin (RAS) and Kinin pathways. Here, after de...

Alternative Titles

Full title

Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) administered via nebulizer

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_plos_journals_2688057447

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_2688057447

Other Identifiers

ISSN

1932-6203

E-ISSN

1932-6203

DOI

10.1371/journal.pone.0271066

How to access this item